Payment overview · 2025
General Payments
$576.28
17 reported records · 13 companies
Healthcare provider profile · identity verified
Arthur Escolin Jimenez, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · VICTORVILLE, CA · NPI 1578532131
Verified facts
What the public records show
CMS Open Payments records show Arthur Escolin Jimenez, M.D. received $576.28 in general payments during 2025 across 17 reported records.
Regeneron Healthcare Solutions, Inc. accounted for 23.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $135.00 | 23.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $125.00 | 21.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $51.79 | 9.0% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $40.49 | 7.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $38.58 | 6.7% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $34.13 | 5.9% | 2 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.88 | 5.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $24.78 | 4.3% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $22.48 | 3.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.87 | 3.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.19 | 3.2% | 1 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $18.05 | 3.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.04 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $576.28 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $135.00 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $51.79 | 2 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Optinose US, Inc., Paratek Pharmaceuticals, Inc. | $48.93 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $40.49 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $38.58 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $34.13 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $24.78 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $22.48 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $19.87 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 90 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
61 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
90 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
61 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1165 | 342 |
| Metformin Hcl | Metformin Hcl | 553 | 172 |
| Alendronate Sodium | Alendronate Sodium | 490 | 136 |
| Losartan Potassium | Losartan Potassium | 407 | 136 |
| Levothyroxine Sodium | Levothyroxine Sodium | 387 | 92 |
| Benazepril Hcl | Benazepril Hcl | 378 | 103 |
| Hydrochlorothiazide | Hydrochlorothiazide | 315 | 95 |
| Tamsulosin Hcl | Tamsulosin Hcl | 312 | 99 |
| Amlodipine Besylate | Amlodipine Besylate | 309 | 105 |
| Potassium Chloride | Potassium Chloride | 285 | 95 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 283 | 81 |
| Famotidine | Famotidine | 255 | 81 |
| Lisinopril | Lisinopril | 250 | 62 |
| Furosemide | Furosemide | 240 | 79 |
| Omeprazole | Omeprazole | 239 | 73 |
| Gabapentin | Gabapentin | 228 | 79 |
| Fluticasone Propionate | Fluticasone Propionate | 186 | 72 |
| Simvastatin | Simvastatin | 180 | 57 |
| Enalapril Maleate | Enalapril Maleate | 179 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 170 | 51 |
| Glipizide | Glipizide | 167 | 50 |
| Allopurinol | Allopurinol | 166 | 41 |
| Buspirone Hcl | Buspirone Hcl | 147 | 43 |
| Finasteride | Finasteride | 142 | 49 |
| Hydralazine Hcl | Hydralazine Hcl | 139 | 41 |
| Clonidine Hcl | Clonidine Hcl | 124 | 43 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 123 | 59 |
| Ibuprofen | Ibuprofen | 117 | 48 |
| Oxybutynin Chloride | Oxybutynin Chloride | 116 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 114 | 36 |
| Ozempic | Semaglutide | 110 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 110 | 29 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 104 | 29 |
| Trazodone Hcl | Trazodone Hcl | 103 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 90 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 90 | 26 |
| Qvar Redihaler | Beclomethasone Dipropionate | 88 | 35 |
| Montelukast Sodium | Montelukast Sodium | 82 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 77 | 59 |
| Carvedilol | Carvedilol | 75 | 26 |
| Chlorthalidone | Chlorthalidone | 73 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 72 | 20 |
| Prednisone | Prednisone | 70 | 38 |
| Azithromycin | Azithromycin | 69 | 55 |
| Dicyclomine Hcl | Dicyclomine Hcl | 66 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | 12 |
| Droplet Pen Needle | Pen Needle, Diabetic | 63 | 18 |
| Jardiance | Empagliflozin | 61 | 16 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 54 | 14 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 52 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 17 |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 47 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 14 |
| Naproxen | Naproxen | 46 | 17 |
| Eliquis | Apixaban | 43 | 14 |
| Megestrol Acetate | Megestrol Acetate | 43 | 11 |
| Meclizine Hcl | Meclizine Hcl | 42 | 21 |
| Sertraline Hcl | Sertraline Hcl | 40 | 14 |
| Terbinafine Hcl | Terbinafine Hcl | 40 | 11 |
| Januvia | Sitagliptin Phosphate | 39 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 38 | suppressed |
| Baclofen | Baclofen | 37 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 13 |
| Glimepiride | Glimepiride | 34 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 33 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 32 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Nitroglycerin | Nitroglycerin | 27 | suppressed |
| Nystatin | Nystatin | 27 | 14 |
| Digoxin | Digoxin | 25 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 20 |
| Clotrimazole | Clotrimazole | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Loperamide | Loperamide Hcl | 23 | 12 |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | suppressed |
| Procto-Med Hc | Hydrocortisone | 21 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 20 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 18 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 12 |
| Colchicine | Colchicine | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 16 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 14 | suppressed |
| Humalog | Insulin Lispro | 14 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 14 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 14 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 12 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $576.28 · 17 records | Regeneron Healthcare Solutions, Inc. | ACCRUFER, AIRSUPRA, DUPIXENT, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, KRYSTEXXA, MOUNJARO, TRELEGY ELLIPTA, XHANCE, XIFAXAN, ZORYVE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error